Researchers at Children's Hospital of Philadelphia (CHOP) highlighted the success of anaplastic lymphoma kinase (ALK) ...

Munich news, health insurance, technology, jobs and other topics for expatriates. The Eye Newspapers covers daily news and offers services for foreigners.

Roche’s Alecensa has become the first drug in the ALK inhibitor class to significantly improve disease-free survival across all disease stages in a phase 3 trial involving patients with ALK ...

It is thought that around 100 people in England will be eligible to receive the drug. The ALK inhibitor is the first drug in the class to be approved for adjuvant use in these patients ...

Neladalkib is a novel brain-penetrant ALK-selective inhibitor created with the aim to overcome limitations observed with currently available ALK inhibitors. Neladalkib is designed to remain active ...

In this group, 5% of patients show molecular alterations in the ALK gene involved in cell multiplication. The use of inhibitors against this oncogene — one of the most effective strategies ...

Researchers at Children's Hospital of Philadelphia (CHOP) highlighted the success of anaplastic lymphoma kinase (ALK) inhibition therapy in treating hereditary neuroblastoma, a rare subset of a common ...